focus high significant and and address highlight Chip, the assessments and Rytelo recent revenue we QX with good our realize this in key Today, help our need trends, commercial population. patient thus morning, to actions opportunities and will value have us you, commercial on unmet I everyone. Thank performance drivers
revenues quarter for approximately coverage policies by supported in described by was demand covered NCCN have lives access. This medical $XX.X that implemented we the FDA Rytelo, consistent clinical million Rytelo for payer guidelines. trials Payers As are previously responsible fourth strong net XX% achieved U.S. of the Chip, label, and/or for with XXXX. Rytelo in the product
patient key drivers primary treatment the revenue. duration on of starts New of are
in commercial IMerge trial setting patients are appears just treatment observed the important patients Rytelo the observed consistent For the in with that market it is research approximately duration of III date longest our median of duration of treatment, note hitting Phase even IMerge. treated that suggests commercial and in to the the X months in to treated
to new patient flatness past respect over months. the observed with starts, have we However, few
Specifically, across utilized have see refractory line ESA first patient third-line starts patients. expectations. from Rytelobin the ESA second RS-negative line come new than though patient eligible, relapse line RS-positive The and and we lower starts second plus our line and plus the even of patient new third segment with majority
starts to of in priority drive is third-line a new so not to FDA Our niche label the population across are our that treatment. we breadth patient
are we in is substantially there particularly patient and we benefit believe on factors We where will relapsed/refractory population. notably patients. ESA focusing differentiated also patients, are RS-negative line are help are other uptakes earlier unsatisfied which There believe accelerate addressing, where Rytelo's we
national we First, variability territory in regional below level the see performance. and account trends, level
territories very improvement competing level. are territories and sales the training Other support opportunity accounts and for performing at Some and accounts where we efforts. well winning local and have are refocusing our and
behaviors. believe market of in key prescribing is or we lower-risk their the a to time with health promotionally MDS front sensitive factor Second, changing the providers, HCPs, care being
HCPs. increase our We efforts are to our by team optimize HCP highlight education. also to educational taking engagement affairs Joe with target will and medical awareness steps
Rytelo often in increase clinical will lines awareness successful in that and We and gain later Rytelo with raise as of they and experience HCP's earlier choose engagement, treatment. patients, work as difficult-to-treat expect lines to we
our mentioned Chip months organization as few medical commercial leadership into Third, changed a and earlier, launch. affairs
a thoughtful launch and excellence of disruption. have a changes balanced minimize implementing We and quickly sense urgency to and approach drive operational
Geron. Vice to joining senior support experienced We Operations. leadership led the Operations, in team responsible President, Commercial joined of business. President, served for Win Gilead approximately XXX ] deep as to background the these Don for as XX in she team brings almost John most Sciences have a Senior and with XXXX Geron, where augmented years supporting analytics and [ Don was Prior recently commercial at a Strategy U.S. Vice efforts. Commercial people October to
include and President, [ in strong and roles role. as with traded biotech joined of experiences Vice He spending another Officer XXXX XX-plus to His and prior X execution. Chief at is teams as publicly working are track and senior a Jim his after year leadership country companies Dan their strategy sales marketing in Marketing. and Amgen including leader insights, successful commercial manager Hassard Together, a Jim at Sales improve most record. Commercial ] Senior career November roles,
capabilities, slide. MDS, and improving in more fully us we to which on the We are Rytelo next our opportunity are effectiveness, the force believe which flat or also for the and refining causes the in several analytics other changes possible assessing implementing have and commercial will scaling promotional I root segmentation targeting will speak our for our capture help revenue up lower-risk implemented significant of such as process sales trends and
U.S. earnings patient As approximately X,XXX and the ESA patients, patients first shown the This recommended with in lower-risk total Rytelo includes NCCN we RS patients negative in XX% status. patients population MDS patients XX,XXX addressable X X,XXX positive estimate that line approximately with Slide RS second guidelines. on deck, XX% X,XXX and of and line third is includes patients our ineligible line in with approximately approximately plus XXXX, of
particularly ESA are our where mentioned, the drug patients. for only on Rytelo RS-negative is I focused As eligible the efforts population relapsed/refractory approved
addressable approximately to IMerge net duration the the based potential Assuming is in treatment Rytelo, by status total the of on patients. X/X treating current U.S. and there observed of price, blockbuster achieve
I Joe turn treatment-eligible to thank will Rytelo. team now that a the their our want over ensure cross-functional for have work timely medical to broad dedicated at patients to and update. for teams access Joe? commercial to hard call I the Geron and
